Cencora price to free cash flow COR

Market value divided by free cash flow over the last twelve months, since 2010.

Today, Oct 23, 2026: 15.6×
10-year median: 13.8×
Against its 10-year history: 65th; percentile: 0 is its lowest day, 100 its highest
10-year range: 5.7× to 62.1×
Peer median: 16.6×

Cencora's price to free cash flow is 15.6× as of Oct 23, 2026.

That is above its ten-year median of 13.8×, higher than on 65% of days in the last ten years.

Over that time it ranged from 5.7× in Oct 2016 to 62.1× in Nov 2025.

The median for 3 medical distribution stocks of a similar size is 16.6×.

Price to free cash flow over time

median 13.8×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	15.6×	14.4×	38.9×
2025	20.6×	14.8×	62.1×
2024	14.6×	11.3×	22.4×
2023	11.9×	11.6×	16.4×
2022	15.4×	10.3×	16.3×
2021	12.4×	8.0×	19.6×
2020	10.9×	8.5×	17.7×
2019	8.6×	7.2×	15.7×
2018	14.6×	9.8×	30.4×
2017	19.3×	6.7×	19.6×
2016	6.3×	4.4×	7.4×
2015	5.8×	5.5×	17.3×
2014	16.7×	16.6×	280×
2013	276×	90.1×	280×
2012	88.3×	60.8×	109×
2011	96.1×	81.8×	130×
2010	102×	90.6×	124×

Against its peers

Companies in Medical - Distribution nearest Cencora's size, closest first, today.

Company	Price to free cash flow
CORCencora	15.6×
CAHCardinal Health	12.8×
MCKMcKesson	18.2×
HSICHenry Schein	16.6×
Peer median	16.6×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Cencora

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.